|
|
|
|
|
|
Sponsors and Collaborators: |
University of California, San Diego National Cancer Institute (NCI) |
Information provided by: | National Cancer Institute (NCI) |
ClinicalTrials.gov Identifier: | NCT00074269 |
RATIONALE: Giving chemotherapy, such as fludarabine and melphalan, before a donor peripheral blood stem cell transplant helps stop the growth of tumor cells. It also stops the patient's immune system from rejecting the donor's stem cells. The donated stem cells may replace the patient's immune system and help destroy any remaining tumor cells (graft-versus-tumor effect). Giving an infusion of the donor's T cells (donor lymphocyte infusion) after the transplant may help increase this effect. Sometimes the transplanted cells from a donor can also make an immune response against the body's normal cells. Giving antithymocyte globulin, cyclosporine, and methotrexate before or after the transplant may stop this from happening.
PURPOSE: This phase II trial is studying how well antithymocyte globulin, high-dose melphalan, fludarabine, and allogeneic peripheral stem cell transplant work in treating patients with metastatic adenocarcinoma of the breast.
Condition | Intervention | Phase |
Breast Cancer |
Drug: anti-thymocyte globulin Drug: cyclosporine Drug: filgrastim Drug: fludarabine phosphate Drug: melphalan Drug: methotrexate Drug: therapeutic allogeneic lymphocytes Procedure: graft-versus-tumor induction therapy Procedure: peripheral blood stem cell transplantation |
Phase II |
Genetics Home Reference related topics: | breast cancer |
MedlinePlus related topics: | Breast Cancer Cancer |
ChemIDplus related topics: | Filgrastim Melphalan Methotrexate Fludarabine Fludarabine monophosphate Cyclosporine Cyclosporin Melphalan hydrochloride Sarcolysin |
Study Type: | Interventional |
Study Design: | Treatment |
Official Title: | Pilot Study Of Allogeneic Peripheral Blood Progenitor Cell Transplantation In Patients With Chemotherapy-Refractory Or Poor-Prognosis Metastatic Breast Cancer |
Estimated Enrollment: | 10 |
Study Start Date: | July 2003 |
Primary Completion Date: | March 2008 (Final data collection date for primary outcome measure) |
OBJECTIVES:
Primary
Secondary
OUTLINE: This is a nonrandomized, pilot study.
Patients are followed at 1, 3, 6, 12, 18, 24, 30, and 36 months.
PROJECTED ACCRUAL: A total of 10 patients will be accrued for this study.
Ages Eligible for Study: | 18 Years to 60 Years |
Genders Eligible for Study: | Female |
Accepts Healthy Volunteers: | No |
DISEASE CHARACTERISTICS:
Histologically confirmed adenocarcinoma of the breast
Meets 1 of the following criteria:
Chemotherapy-unresponsive disease defined as 1 of the following:
Measurable or evaluable disease* defined as the following:
Evaluable lesions apparent on clinical exam, x-ray, CT scan, or MRI which do not fit the criteria for measurability (e.g., ill-defined post-surgical masses or masses assessable in 1 dimension only)
Available HLA-identical sibling donor
Hormone receptor status:
Estrogen receptor negative or positive
PATIENT CHARACTERISTICS:
Age
Sex
Menopausal status
Performance status
Life expectancy
Hematopoietic
Hepatic
Renal
Cardiovascular
Pulmonary
Other
PRIOR CONCURRENT THERAPY:
Biologic therapy
Chemotherapy
Endocrine therapy
Radiotherapy
Surgery
Other
United States, California | |||||
Rebecca and John Moores UCSD Cancer Center | |||||
La Jolla, California, United States, 92093-0658 |
University of California, San Diego |
National Cancer Institute (NCI) |
Principal Investigator: | Edward D. Ball, MD | University of California, San Diego |
Clinical trial summary from the National Cancer Institute's PDQ® database 
  |
Study ID Numbers: | CDR0000343758, UCSD-020815 |
First Received: | December 10, 2003 |
Last Updated: | July 23, 2008 |
ClinicalTrials.gov Identifier: | NCT00074269 |
Health Authority: | United States: Federal Government |
|
|
|
|
|